PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, USA; Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA, USA; Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: George.r.painter@emory.edu.\', \'Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, USA.\', \'Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds LS2 9LH, UK.\', \'Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1879-6257(21)00066-310.1016/j.coviro.2021.06.003
?:doi
?:hasPublicationType
?:journal
  • Current opinion in virology
is ?:pmid of
?:pmid
?:pmid
  • 34271264
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.69
?:rankingScore_hIndex
  • 50
is ?:relation_isRelatedTo_publication of
?:title
  • Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34271264>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34271264>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all